A Phase 3 Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants with HIV-1 Virologically Suppressed on Antiretroviral Therapy
- Schmidt, Tina (Primary Chief Investigator (PCI))
- Silvers, Julie (Project Manager)
Project: Research